Aspirin professional labeling indication for suspected acute MI proposed by FDA.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN INDICATION FOR SUSPECTED ACUTE MI PROPOSED by FDA in a notice published in the June 13 Federal Register. The agency's proposal to amend the tentative final monograph for OTC internal analgesic, antipyretic and antirheumatic drug products calls for changes to the professional labeling of products containing aspirin, buffered aspirin and aspirin in combination with antacid. Amendments would include an indication for reduction of "the risk of vascular mortality in people with suspected acute myocardial infarction (MI)." Written comments on the proposal are due Sept. 11.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning